Publication date: October 25, 2024
Category: Medicines for humans
Link: MAX, 26/2024
- The goal is to demonstrate what the pharmacogenomic biomarker database is and its implications for the national healthcare system.
- The hybrid session, scheduled for November 4, requires pre-registration.
- The event will be attended by representatives of various national interest groups, as well as an international representation of experts in the field of pharmacogenetics from Ibero-America.
The Spanish Agency for Medicines and Health Products (AEMPS) will hold an information day on pharmacogenomic biomarkers on November 4th to show what the database is, how its implementation will be carried out, in addition to the clinical implementation of pharmacogenetics. in the national health system and from the perspective of the agents involved.
The event will be held in a hybrid format, both in person at AEMPS headquarters and onlineboth require pre-registration. For personal participation, 40 registrations are activated, which will be completed in the order of registration.
The session will be welcomed by Maria Jesús Lamas, Director of AEMPS, and will feature presentations by database promoters Ana López de la Rica, Deputy Head of the Department of Medicines for Human Use of AEMPS, Sara González, Technical Specialist of AEMPS, in collaboration with Adrian Llerena, Director of the University Institute of Biosanitary Research of Extremadura (INUBE). Vangelis G. Manolopoulos, Director of the National Medicines Organization, will also speak at the event.
The day will include an information table bringing together representatives of various interest groups at the national level, as well as another round table with pharmacogenetics experts from Ibero-America. The event will be closed by Robert Nistico, Director of the Italian Pharmaceutical Agency (AIFA) and Antonio Blazquez, Head of the Department of Medicines for Human Use (AEMPS).
The meeting will be recorded and streamed live on the AEMPS YouTube channel.